doi: 10.1007/BF00195603.
Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor
- PMID: 3494820
- DOI: 10.1007/BF00195603
Item in Clipboard
Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor
J Neurooncol.
1987.
Abstract
Autologous brain tumor specific CTLs were induced from the patient's PBL by a mixed lymphocyte-tumor culture, and were maintained for more than 2 months in a medium containing exogenous IL-2. The autologous T cell line containing specific CTL was administered into the tumor-bed for the treatment of malignant glioma. In 2 cases out of 5, tumors regressed more than 50% in diameter. One of these patients is still alive now with full of his social activities, and it is 104 weeks after the initiation of the immunotherapy. Autologous T cell lines were safely administered in all cases without any complications nor toxicities.
Similar articles
-
Induction of human glioma-specific cytotoxic T-lymphocyte lines by autologous tumor stimulation and interleukin 2.J Neurooncol. 1986;4(1):55-64. doi: 10.1007/BF02158003. J Neurooncol. 1986. PMID: 3489081
-
Specific adoptive immunotherapy of malignant glioma with long-term cytotoxic T lymphocyte line expanded in T-cell growth factor. Experimental study and future prospects.Neurosurg Rev. 1984;7(1):37-54. doi: 10.1007/BF01743289. Neurosurg Rev. 1984. PMID: 6611523
-
[Adoptive immunotherapy in patients with malignant glioma].Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1930-2. Gan To Kagaku Ryoho. 1987. PMID: 3496052 Japanese.
-
Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes.Neurol Res. 1997 Apr;19(2):145-52. doi: 10.1080/01616412.1997.11740788. Neurol Res. 1997. PMID: 9175143 Review.
-
[CTL precursor-oriented peptide vaccine therapy for malignant glioma].Nihon Rinsho. 2005 Sep;63 Suppl 9:582-7. Nihon Rinsho. 2005. PMID: 16201585 Review. Japanese. No abstract available.
Cited by
-
Immunotherapy for the treatment of glioblastoma.Cancer J. 2012 Jan-Feb;18(1):59-68. doi: 10.1097/PPO.0b013e3182431a73. Cancer J. 2012. PMID: 22290259 Free PMC article. Review.
-
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162. Sci Transl Med. 2014. PMID: 25378643 Free PMC article.
-
Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.Mol Cancer Ther. 2014 Dec;13(12):3024-36. doi: 10.1158/1535-7163.MCT-14-0400. Epub 2014 Sep 25. Mol Cancer Ther. 2014. PMID: 25256739 Free PMC article.
-
Toward effective immunotherapy for the treatment of malignant brain tumors.Neurotherapeutics. 2009 Jul;6(3):527-38. doi: 10.1016/j.nurt.2009.04.003. Neurotherapeutics. 2009. PMID: 19560742 Free PMC article. Review.
-
Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation.Jpn J Cancer Res. 1997 Mar;88(3):289-95. doi: 10.1111/j.1349-7006.1997.tb00380.x. Jpn J Cancer Res. 1997. PMID: 9140114 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical